Center For Scientific Review; Notice of Closed Meetings, 85584 [2016-28415]
Download as PDF
85584
Federal Register / Vol. 81, No. 228 / Monday, November 28, 2016 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Psychiatric Disorders and
Addiction.
Date: December 13, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Samuel C Edwards, Ph.D.,
IRG Chief, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5210, MSC 7846, Bethesda, MD
20892, (301) 435–1246, edwardss@
csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Member
Conflict: Neurovirology, Neuroimmunology,
Neurodevelopmental Disorders, and
Anticancer Drugs.
Date: December 15, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Samuel C. Edwards, Ph.D.,
IRG Chief, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 5210, MSC 7846, Bethesda, MD
20892, (301) 435–1246, edwardss@
csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: November 21, 2016.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–28415 Filed 11–25–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities Under Emergency Review by
the Office of Management and Budget
The Substance Abuse and Mental
Health Services Administration
(SAMHSA) has submitted the following
request (see below) for emergency OMB
review under the Paperwork Reduction
Act (44 U.S.C. Chapter 35). OMB
approval has been requested by January
12, 2017. A copy of the information
collection plans may be obtained by
calling the SAMHSA Reports Clearance
Officer at (240) 276–1243.
Title: Notification of Intent to Use
Schedule III, IV, or V Opioid Drugs for
the Maintenance and Detoxification
Treatment of Opiate Addiction by a
‘‘Qualifying Other Practitioner’’—NEW.
OMB Number: 0930—New.
Frequency: On Going.
Affected public: Nurse Practitioners
and Physician Assistants.
The Substance Abuse and Mental
Health Services Administration
(SAMHSA) is requesting an emergency
Office of Management and Budget
(OMB) review and approval of the
Notification of Intent to Use Schedule
III, IV, or V Opioid Drugs for the
Number of
respondents
mstockstill on DSK3G9T082PROD with NOTICES
Purpose of submission
Notification of Intent for Qualifying Other Practitioner to Use Schedule III,
IV, or V Opioid Drugs for the Maintenance and Detoxification Treatment
of Opiate Addiction by a ‘‘Qualifying Other Practitioner’’ under 21 USC
§ 823(g)(2)—Nurse Practitioners ..................................................................
Notification of Intent for Qualifying Other Practitioner to Use Schedule III,
IV, or V Opioid Drugs for the Maintenance and Detoxification Treatment
of Opiate Addiction by a ‘‘Qualifying Other Practitioner’’ under 21 USC
§ 823(g)(2)—Physician Assistants ...............................................................
Total ..........................................................................................................
VerDate Sep<11>2014
21:15 Nov 25, 2016
Jkt 241001
PO 00000
Frm 00077
Fmt 4703
Sfmt 4703
Maintenance and Detoxification
Treatment of Opiate Addiction by a
‘‘Qualifying Other Practitioner. The
Notification of Intent would allow
SAMHSA to determine whether other
practitioners are eligible to prescribe
certain approved narcotic treatment
medications for the maintenance or
detoxification treatment of opioid
addiction.
This Notification of Intent is a result
of the Comprehensive Addiction and
Recovery Act (Pub. L. 114–198), which
was signed into law on July 22, 2016.
The law establishes criteria for nurse
practitioners (NPs) and physician
assistants (PAs) to qualify for a waiver
to prescribe covered medications. To be
eligible for a waiver, the NP or PA must:
be licensed under State law to prescribe
schedule III, IV, or V medications for the
treatment of pain; fulfill qualification
requirements in the law for training and
experience; and fulfill qualification
requirements in the law for appropriate
supervision by a qualifying physician.
SAMHSA has the responsibility to
receive, review, approve, or deny waiver
requests.
Practitioners who meet the statutory
requirements will be eligible to
prescribe only those opioid treatment
medications that are controlled in
Schedules III, IV, or V, under the
Controlled Substance Act (CSA), that
are specifically approved by the Food
and Drug Administration (FDA) for the
treatment of opioid addiction, and are
not the subject of an ‘‘adverse
determination.’’ The only medications
that currently fulfill these requirements
are ones that contain the active
ingredient buprenorphine.
Given the severity of the opioid
epidemic, SAMHSA is requesting an
emergency OMB approval. Emergency
OMB approval will enable NPs and PAs
to dramatically increase access to
buprenorphine among individuals with
opioid use disorder.
The following table is the estimated
hour burden:
Responses/
respondent
Burden hours
Total burden
hours
816
1
.066
54
590
1
.066
39
1,406
........................
........................
93
E:\FR\FM\28NON1.SGM
28NON1
Agencies
[Federal Register Volume 81, Number 228 (Monday, November 28, 2016)]
[Notices]
[Page 85584]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-28415]
[[Page 85584]]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Member Conflict: Psychiatric Disorders and Addiction.
Date: December 13, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Samuel C Edwards, Ph.D., IRG Chief, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge
Drive, Room 5210, MSC 7846, Bethesda, MD 20892, (301) 435-1246,
edwardss@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Member Conflict: Neurovirology, Neuroimmunology,
Neurodevelopmental Disorders, and Anticancer Drugs.
Date: December 15, 2016.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Samuel C. Edwards, Ph.D., IRG Chief, Center for
Scientific Review, National Institutes of Health, 6701 Rockledge
Drive, Room 5210, MSC 7846, Bethesda, MD 20892, (301) 435-1246,
edwardss@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: November 21, 2016.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-28415 Filed 11-25-16; 8:45 am]
BILLING CODE 4140-01-P